FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208796988> ?p ?o ?g. }

• W3208796988 endingPage "e442" @default.
• W3208796988 startingPage "e442" @default.
• W3208796988 abstract "Purpose/Objective(s)The PACIFIC Trial established durvalumab consolidation after definitive chemo-radiation (CRT) as the standard of care for Stage III Non-small cell lung cancer (NSCLC) in those not undergoing surgery. The rate of G3+ pneumonitis risk in this trial was less than 5% in the durvalumab arm. However, there is limited data regarding radiotherapy (RT) lung dosimetry from the PACIFIC trial to determine whether it accurately reflect real-world patients with locally advanced NSCLC who often require high lung dose to obtain target coverage. It is unclear whether established constraints accurately predict pneumonitis risk in this population. We aim to report outcomes and pneumonitis risk in a real word population of patients treated with CRT and durvalumab and determine risk of pneumonitis based on RT lung dosimetry.Materials/MethodsWe identified patients treated with CRT and durvalumab at a single institution for NSCLC not undergoing surgical resection. Patients were excluded if RT dosimetry was not available. NCI CTCAE v5.0 was used for grading pneumonitis. Differentiation of radiation pneumonitis (RP) vs durvalumab pneumonitis (DP) was determined by a radiation oncologist. Kaplan-Meier method was used to analyze overall survival (OS), progression free survival (PFS), and pneumonitis incidence and were compared using log rank test.Results40 patients treated with CRT and consolidative durvalumab were identified with median follow-up of 19 months. 90% of patients were Stage IIIA or IIIB (IIA-IIIC). Median RT dose was 63 Gy (54-70 Gy). Median MLD was 16 Gy (7-21 Gy). Median lung V20 was 29.5% (10%-38%). OS and PFS at 2 years was 69.7% was 60.3% respectively. Grade 2+ and 3+ combined RP and DP for the overall cohort was 29.0% and 24.0% respectively. Median time to pneumonitis from completion date of RT was 129 days. 22.5% (9/40) of patients required steroids for treatment of pneumonitis. 15% (6/40) of patients had a new O2 requirement attributed to pneumonitis. Pneumonitis led to discontinuation of durvalumab in 20% (8/40) of patients. Of the 9 cases of pneumonitis, 7 (77.8%) were consider RP, and 2 (22.2%) DP. Grade 2+ pneumonitis risk was 64.5% in patients with lung V20 > 30% versus 8.3% in patients with lung V20 ≤ 30% (P > 0.001). Grade 2+ pneumonitis risk was 59.4% in patients with a MLD > 17 Gy versus 8.3% in those with MLD ≤ 17 Gy (P < 0.001). Grade 3+ pneumonitis risk was 51.5% in patients with lung V20 > 30% versus 8.3% in patients with lung V20 ≤ 30% (P = 0.003). Grade 3+ pneumonitis risk was 47.0% in patients with a MLD > 17 Gy versus 8.3% in those with MLD ≤ 17 Gy (P < 0.005).ConclusionRisk of pneumonitis in this single institution study of real-world patients treated with definitive CRT and durvalumab was higher than reported the PACIFIC trial. Pneumonitis risk was markedly elevated in patients with lung V20 > 30% or MLD > 17 Gy. Larger series are needed to determine optimal dose constraints in this patient population in the era of durvalumab. The PACIFIC Trial established durvalumab consolidation after definitive chemo-radiation (CRT) as the standard of care for Stage III Non-small cell lung cancer (NSCLC) in those not undergoing surgery. The rate of G3+ pneumonitis risk in this trial was less than 5% in the durvalumab arm. However, there is limited data regarding radiotherapy (RT) lung dosimetry from the PACIFIC trial to determine whether it accurately reflect real-world patients with locally advanced NSCLC who often require high lung dose to obtain target coverage. It is unclear whether established constraints accurately predict pneumonitis risk in this population. We aim to report outcomes and pneumonitis risk in a real word population of patients treated with CRT and durvalumab and determine risk of pneumonitis based on RT lung dosimetry. We identified patients treated with CRT and durvalumab at a single institution for NSCLC not undergoing surgical resection. Patients were excluded if RT dosimetry was not available. NCI CTCAE v5.0 was used for grading pneumonitis. Differentiation of radiation pneumonitis (RP) vs durvalumab pneumonitis (DP) was determined by a radiation oncologist. Kaplan-Meier method was used to analyze overall survival (OS), progression free survival (PFS), and pneumonitis incidence and were compared using log rank test. 40 patients treated with CRT and consolidative durvalumab were identified with median follow-up of 19 months. 90% of patients were Stage IIIA or IIIB (IIA-IIIC). Median RT dose was 63 Gy (54-70 Gy). Median MLD was 16 Gy (7-21 Gy). Median lung V20 was 29.5% (10%-38%). OS and PFS at 2 years was 69.7% was 60.3% respectively. Grade 2+ and 3+ combined RP and DP for the overall cohort was 29.0% and 24.0% respectively. Median time to pneumonitis from completion date of RT was 129 days. 22.5% (9/40) of patients required steroids for treatment of pneumonitis. 15% (6/40) of patients had a new O2 requirement attributed to pneumonitis. Pneumonitis led to discontinuation of durvalumab in 20% (8/40) of patients. Of the 9 cases of pneumonitis, 7 (77.8%) were consider RP, and 2 (22.2%) DP. Grade 2+ pneumonitis risk was 64.5% in patients with lung V20 > 30% versus 8.3% in patients with lung V20 ≤ 30% (P > 0.001). Grade 2+ pneumonitis risk was 59.4% in patients with a MLD > 17 Gy versus 8.3% in those with MLD ≤ 17 Gy (P < 0.001). Grade 3+ pneumonitis risk was 51.5% in patients with lung V20 > 30% versus 8.3% in patients with lung V20 ≤ 30% (P = 0.003). Grade 3+ pneumonitis risk was 47.0% in patients with a MLD > 17 Gy versus 8.3% in those with MLD ≤ 17 Gy (P < 0.005). Risk of pneumonitis in this single institution study of real-world patients treated with definitive CRT and durvalumab was higher than reported the PACIFIC trial. Pneumonitis risk was markedly elevated in patients with lung V20 > 30% or MLD > 17 Gy. Larger series are needed to determine optimal dose constraints in this patient population in the era of durvalumab." @default.
• W3208796988 created "2021-11-08" @default.
• W3208796988 creator A5009585933 @default.
• W3208796988 creator A5020114989 @default.
• W3208796988 creator A5050392689 @default.
• W3208796988 creator A5052336062 @default.
• W3208796988 creator A5074737662 @default.
• W3208796988 creator A5087883440 @default.
• W3208796988 date "2021-11-01" @default.
• W3208796988 modified "2023-10-03" @default.
• W3208796988 title "Risk of Pneumonitis in Patients With Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemo-RT and Durvalumab Consolidation" @default.
• W3208796988 doi "https://doi.org/10.1016/j.ijrobp.2021.07.1250" @default.
• W3208796988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701465" @default.
• W3208796988 hasPublicationYear "2021" @default.
• W3208796988 type Work @default.
• W3208796988 sameAs 3208796988 @default.
• W3208796988 citedByCount "2" @default.
• W3208796988 countsByYear W32087969882022 @default.
• W3208796988 countsByYear W32087969882023 @default.
• W3208796988 crossrefType "journal-article" @default.
• W3208796988 hasAuthorship W3208796988A5009585933 @default.
• W3208796988 hasAuthorship W3208796988A5020114989 @default.
• W3208796988 hasAuthorship W3208796988A5050392689 @default.
• W3208796988 hasAuthorship W3208796988A5052336062 @default.
• W3208796988 hasAuthorship W3208796988A5074737662 @default.
• W3208796988 hasAuthorship W3208796988A5087883440 @default.
• W3208796988 hasBestOaLocation W32087969881 @default.
• W3208796988 hasConcept C121608353 @default.
• W3208796988 hasConcept C126322002 @default.
• W3208796988 hasConcept C126838900 @default.
• W3208796988 hasConcept C143998085 @default.
• W3208796988 hasConcept C2776256026 @default.
• W3208796988 hasConcept C2777701055 @default.
• W3208796988 hasConcept C2777714996 @default.
• W3208796988 hasConcept C2777742743 @default.
• W3208796988 hasConcept C2779524853 @default.
• W3208796988 hasConcept C2780030458 @default.
• W3208796988 hasConcept C2908647359 @default.
• W3208796988 hasConcept C2908954928 @default.
• W3208796988 hasConcept C509974204 @default.
• W3208796988 hasConcept C71924100 @default.
• W3208796988 hasConcept C99454951 @default.
• W3208796988 hasConceptScore W3208796988C121608353 @default.
• W3208796988 hasConceptScore W3208796988C126322002 @default.
• W3208796988 hasConceptScore W3208796988C126838900 @default.
• W3208796988 hasConceptScore W3208796988C143998085 @default.
• W3208796988 hasConceptScore W3208796988C2776256026 @default.
• W3208796988 hasConceptScore W3208796988C2777701055 @default.
• W3208796988 hasConceptScore W3208796988C2777714996 @default.
• W3208796988 hasConceptScore W3208796988C2777742743 @default.
• W3208796988 hasConceptScore W3208796988C2779524853 @default.
• W3208796988 hasConceptScore W3208796988C2780030458 @default.
• W3208796988 hasConceptScore W3208796988C2908647359 @default.
• W3208796988 hasConceptScore W3208796988C2908954928 @default.
• W3208796988 hasConceptScore W3208796988C509974204 @default.
• W3208796988 hasConceptScore W3208796988C71924100 @default.
• W3208796988 hasConceptScore W3208796988C99454951 @default.
• W3208796988 hasIssue "3" @default.
• W3208796988 hasLocation W32087969881 @default.
• W3208796988 hasLocation W32087969882 @default.
• W3208796988 hasOpenAccess W3208796988 @default.
• W3208796988 hasPrimaryLocation W32087969881 @default.
• W3208796988 hasRelatedWork W1879151775 @default.
• W3208796988 hasRelatedWork W2064979843 @default.
• W3208796988 hasRelatedWork W2348376668 @default.
• W3208796988 hasRelatedWork W2384648089 @default.
• W3208796988 hasRelatedWork W2392185351 @default.
• W3208796988 hasRelatedWork W2417657575 @default.
• W3208796988 hasRelatedWork W3032810950 @default.
• W3208796988 hasRelatedWork W3083096714 @default.
• W3208796988 hasRelatedWork W3115829157 @default.
• W3208796988 hasRelatedWork W4214773217 @default.
• W3208796988 hasVolume "111" @default.
• W3208796988 isParatext "false" @default.
• W3208796988 isRetracted "false" @default.
• W3208796988 magId "3208796988" @default.
• W3208796988 workType "article" @default.